1. In Vivo

European Life Sciences Start-Ups Maintain Early Investor Allure

 
• By John Hodgson and Mike Ward

Venture capital investment in life sciences companies continues to rise. In 2017, biopharma and medtech start-ups raised $19.7 billion worldwide. European businesses retained a robust share of that global take and investors expect that trend to continue.

V1802_Euro-Start-UP-Feature-image.jpg

It has never been a better time for life sciences start-ups to raise money from venture sources. In 2017, according to data compiled by Informa Pharma Intelligence, venture capitalists invested a total of $19.7 billion in the sector across the globe – some $15.1 billion allocated to 512 biopharma-focused opportunities while $4.6 billion was invested in 107 medtech businesses. Europe’s share of the global take was nearly $4 billion, more than double what it was in 2013.

With new funds being raised and non-European investors looking for bargains, the prospects for European biopharma, medtech and digital health...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Global Vision

More from In Vivo

Podcast: Brain+ CEO Discusses “Groundbreaking” Potential Of CST Assistant For Dementia Patients

 
• By Anabel Costa-Ferreira

Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.

Behind The Buyout: Dispatches From The Dealmaking Table

 
• By Jo Shorthouse

In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.

Crisis Or Opportunity? US MFN Policy Could Test Japan’s Appetite For Reforms

 
• By Lisa Takagi

While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.